BMEA

Biomea Fusion Inc

0.5822

Nov 13 • 3:59 PM ET +0.0195 (3.47%)

0.5706

Aftermarket • 6:59 PM ET -0.0116 (-1.99%)

Healthcare Biotechnology USA Nano NASD

Peers: VTVT ALT GPCR CRBP SEPN KURA SNDX VKTX LXRX SANA

| Held by: VTI VXF IWC BUSM BTEC CHNA

Scroll to Statements

Index	-
Market Cap	42.32M
Enterprise Value	16.06M
Income	-22.31M
Sales	0.00M
Book/sh	0.10
Cash/sh	0.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	41
IPO	Apr 16, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.58
P/C	1.58
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.17
Current Ratio	2.17
Debt/Eq	0.07
LT Debt/Eq	0.00
Option/Short	Yes / No

EPS (ttm)	-0.31
EPS next Y	-0.72
EPS next Q	-0.21
EPS this Y	45.35%
EPS next Y	-11.84%
EPS next 5Y	12.67%
EPS past 3/5Y	24.92% -46.26%
Sales past 3/5Y	- -
EPS Y/Y TTM	87.11%
Sales Y/Y TTM	-
EPS Q/Q	68.92%
Sales Q/Q	-
Earnings	Nov 10 AMC
EPS/Sales Surpr.	56.56% -

Insider Own	6.76%
Insider Trans	0.00%
Inst Own	40.46%
Inst Trans	0.26%
ROA	-53.59%
ROE	-192.32%
ROIC	-294.15%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.45%
SMA50	-48.66%
SMA200	-56.41%
Trades

Shs Outstand	72.68M
Shs Float	67.76M
Short Float	22.45%
Short Ratio	7.00
Short Interest	15.21M
52W High	2.24 -73.97%
52W Low	0.54 7.79%
Volatility	12.47% 12.29%
ATR (14)	0.08
RSI (14)	33.44
Beta	-0.14
Rel Volume	0.26
Avg Volume	2.17M
Volume	563,590

Perf Week	2.72%
Perf Month	-30.39%
Perf Quarter	-56.87%
Perf Half Y	-56.87%
Perf YTD	-53.05%
Perf Year	-54.87%
Perf 3Y	-93.04%
Perf 5Y	-95.09%
Perf 10Y	-
Recom	1.50
Target Price	6.43
Prev Close	0.56
Price	0.58
Change %	3.47%

Consensus

Buy

Avg. Price Target

$6.43

Implied Upside

+1,004.4%

Analysts12incl. previous ratings

Rating Distribution10 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jan 13, 2026	Initiated	RRodman & Renshaw	Buy	$8	+1,274.1%
Aug 28, 2025	Initiated	JJefferies	Buy	$5	+758.8%
Jun 03, 2025	Resumed	PPiper Sandler	Overweight	$7	+1,102.3%
Oct 09, 2024	Initiated	EEdward Jones	Buy	$128	+21,885.6%
Sep 27, 2024	Upgrade	TTruist	Hold → Buy	$54	+9,175.2%
Sep 27, 2024	Upgrade	RRodman & Renshaw	Neutral → Buy	$18	+2,991.7%
Aug 29, 2024	Initiated	CCapitalOne	Overweight	$25	+4,194.1%
Jun 11, 2024	Downgrade	TTruist	Buy → Hold
Jun 07, 2024	Downgrade	BBarclays	Overweight → Equal Weight	$30 → $5	+758.8%
Apr 02, 2024	Downgrade	JJP Morgan	Overweight → Neutral	$51 → $14	+2,304.7%
Feb 06, 2024	Initiated	TTruist	Buy	$55	+9,346.9%
Jul 27, 2023	Initiated	BScotiabank	Sector Outperform	$41	+6,942.3%
Jun 26, 2023	Downgrade	JJefferies	Buy → Hold
May 12, 2023	Initiated	BBarclays	Overweight	$50	+8,488.1%
Mar 29, 2023	Reiterated	OOppenheimer	Outperform	$25 → $47	+7,972.8%
Mar 28, 2023	Reiterated	HH.C. Wainwright	Buy	$37 → $44	+7,457.5%
Feb 24, 2023	Initiated	CCitigroup	Buy	$20	+3,335.2%
Jun 02, 2022	Resumed	HH.C. Wainwright	Buy	$16	+2,648.2%
Jan 12, 2022	Initiated	HH.C. Wainwright	Buy	$13	+2,132.9%
Dec 17, 2021	Initiated	OOppenheimer	Outperform	$22	+3,678.8%

Nov-12-26 04:01PM	Biomea Fusion to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.89%
Nov-10-26 04:05PM	Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) -8.07% +11.68%
07:00AM	Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek 2026 (GlobeNewswire)
Oct-13-26 04:08PM	Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist (GlobeNewswire) -7.35% -33.81%
Oct-12-26 04:30PM	Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist (GlobeNewswire)
07:03AM	Loading…
Sep-23-26 07:03AM	Biomea Fusion Announces Termination of Proposed Public Offering of Securities (GlobeNewswire) -15.29%
Sep-22-26 04:05PM	Biomea Fusion Announces Proposed Public Offering of Securities (GlobeNewswire)
Sep-03-26 08:00AM	Biomea Fusion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-26 07:00AM	Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes (GlobeNewswire) +16.06%
Aug-13-26 07:00AM	Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity (GlobeNewswire)
Aug-05-26 04:05PM	Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
Jun-05-26 07:32PM	Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study (GlobeNewswire) -7.30% -9.45%
Jun-03-26 08:00AM	Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity (GlobeNewswire) -5.11%
May-12-26 04:05PM	Biomea Fusion to Participate at Upcoming Investor Conferences (GlobeNewswire) -6.33%
May-11-26 04:54PM	Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
05:50PM	Loading…
May-05-26 05:50PM	Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions (GlobeNewswire) +5.26%
Apr-27-26 05:37PM	Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment (GlobeNewswire) -8.47% -11.56%
Mar-31-26 07:00AM	Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies (GlobeNewswire) +15.91%
Mar-24-26 04:05PM	Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights (GlobeNewswire) +7.96%
Mar-14-26 04:30AM	Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 (GlobeNewswire)
Feb-26-26 11:14PM	Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf. (MarketBeat) -5.52%
Feb-19-26 07:00AM	Biomea Fusion to Participate at Upcoming Investor Conferences (GlobeNewswire)
Jan-19-26 08:01AM	Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target (Insider Monkey)
Jan-15-26 08:48AM	Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones (MarketBeat) -13.89%
Jan-12-26 08:00AM	Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones (GlobeNewswire)
Dec-17-25 07:00AM	Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-25 06:35PM	Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 (GlobeNewswire) +14.93%
Dec-05-25 07:00AM	Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Dec-01-25 04:10PM	Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) -7.34% -5.22%
04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Loading…
Nov-24-25 07:00AM	Biomea Fusion to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-10-25 07:00AM	Biomea Fusion to Participate at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-05-25 07:00AM	Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek 2025 (GlobeNewswire) +6.35%
Nov-04-25 04:05PM	Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-30-25 08:00AM	Biomea Fusion to Present Poster Presentations at ObesityWeek2025 (GlobeNewswire)
Oct-27-25 08:00AM	Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist (GlobeNewswire)
Oct-21-25 07:05PM	Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series (GlobeNewswire) -9.43%
Oct-07-25 08:00AM	Biomea Fusion Announces Pricing of Public Offering of Securities (GlobeNewswire) -30.90%
Oct-06-25 04:18PM	Biomea Fusion Announces Proposed Public Offering of Securities (GlobeNewswire) +24.19%
04:03PM	Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations (GlobeNewswire)
Oct-01-25 07:00AM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-25 07:00AM	Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update (GlobeNewswire)
Aug-28-25 09:39AM	Five Below upgraded, Bill downgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 04:05PM	Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-24-25 07:00AM	Biomea Fusion Appoints Julianne Averill to its Board of Directors (GlobeNewswire)
Jun-24-25 01:07PM	Biomea Fusion announces presentation of icovamenib preclinical, clinical data (TipRanks) +11.24%
Jun-23-25 07:00AM	Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire) -6.63%
Jun-18-25 07:00AM	Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates (GlobeNewswire) -34.14%
Jun-17-25 11:15PM	Biomea Fusion Announces Pricing of Public Offering of Securities (GlobeNewswire) +10.27%
04:33PM	Biomea Fusion Announces Proposed Public Offering of Securities (GlobeNewswire)
Jun-13-25 06:45AM	Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 (GlobeNewswire) -9.58%
Jun-03-25 12:00PM	Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know (Zacks) +60.65%
May-14-25 04:05PM	Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia (GlobeNewswire) -10.43%
May-05-25 04:05PM	Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) -8.26% -16.50%
Apr-02-25 09:35AM	After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) (Zacks) +8.54%
Apr-01-25 04:01PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.57%
09:35AM	After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) (Zacks)
Mar-31-25 04:10PM	Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights (GlobeNewswire) -7.39%
09:35AM	After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA) (Zacks)
Mar-25-25 07:00PM	Biomea Fusion Announces Leadership Transition (GlobeNewswire) -6.32%
08:50AM	Biomea Fusion announces presentation of icovamenib preclinical, clinical data (TipRanks)
Mar-24-25 08:30AM	Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose (GlobeNewswire)
Mar-03-25 08:00AM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.65%
Feb-27-25 08:00AM	Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (GlobeNewswire)
Jan-13-25 09:00AM	Biomea Fusion to Become a Diabetes and Obesity Medicines Company (GlobeNewswire)
09:00AM	Biomea Fusion to Become a Diabetes & Obesity Medicines Company (GlobeNewswire)
Jan-07-25 09:00AM	Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study (GlobeNewswire)
Jan-06-25 09:04AM	Heres Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) +5.09%
07:00AM	Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-24 10:41AM	Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday? (Benzinga) -20.68%
08:10AM	Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (GlobeNewswire)
Dec-16-24 06:15PM	Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) (GlobeNewswire)
Dec-12-24 05:02PM	Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire) -5.54%
05:02PM	Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Dec-09-24 04:01PM	Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia (GlobeNewswire) -5.08%
Dec-06-24 08:00AM	Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia (GlobeNewswire)
Dec-02-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.50%
Nov-18-24 08:00AM	Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) (GlobeNewswire)
Nov-01-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-24 04:00PM	Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate (GlobeNewswire) -14.26% -9.38%
Oct-29-24 04:46PM	Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-21-24 09:00AM	Biomea Fusion Announces Approval of icovamenib as International Nonproprietary Name for BMF-219 (GlobeNewswire)
Oct-15-24 04:05PM	Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy (GlobeNewswire) +5.38%
Oct-10-24 08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
Oct-07-24 09:00AM	Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) (GlobeNewswire)
Oct-01-24 09:00AM	Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts (GlobeNewswire) -5.94%
Sep-27-24 12:20PM	FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate (Benzinga)
11:13AM	Biomeas stock bounces back as FDA lifts clinical hold on diabetes trials (Pharmaceutical Technology)
Sep-26-24 02:00PM	FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials (GlobeNewswire) +9.12%
Aug-14-24 09:55AM	Wall Street Analysts Think Biomea Fusion (BMEA) Could Surge 317.86%: Read This Before Placing a Bet (Zacks)
Aug-01-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-24 10:54PM	BMEA Stock Earnings: Biomea Fusion Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Jun-29-24 08:32PM	Biomea Fusion, Inc. (BMEA): Why Did Analysts Give This Biotech Penny Stock a Moderate Buy Rating? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 02:21AM	Why Are Hedge Funds Shorting Biomea Fusion, Inc. (BMEA)? (Insider Monkey)
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey) -14.59%
Jun-17-24 09:00AM	Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies (GlobeNewswire) -9.75%
Jun-11-24 11:34AM	Biomea Fusion, Inc. (NASDAQ:BMEA) Downgraded by Barclays (Insider Monkey)
09:06AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Erdtmann Rainer M	See Remarks	Dec 11 '25	Buy	1.43	30,000	42,999	723,027	Dec 15 04:15 PM
Hitchcock Michael J.M.	Interim CEO	Dec 02 '25	Buy	0.99	100,000	99,180	115,000	Dec 04 04:15 PM
Erdtmann Rainer M	See Remarks	Nov 28 '25	Buy	1.10	40,000	44,052	683,027	Dec 02 04:15 PM
Erdtmann Rainer M	See Remarks	Dec 01 '25	Buy	1.05	10,000	10,500	693,027	Dec 02 04:15 PM

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

Interim CEO & DirectorDr. Michael J. M. Hitchcock Ph.D.

Co-FounderMr. Ramses M. Erdtmann

Chief Technical & Quality OfficerMr. Heow Tan

Senior Vice President of LegalCaroline Perez- Dupont J.D.

Executive Vice President of ResearchDr. Thorsten Kirschberg Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

BMEA

Biomea Fusion Inc

Upgrade your Finviz experience

All the Features.
Half the Price.